1. Home
  2. BEAM vs NIC Comparison

BEAM vs NIC Comparison

Compare BEAM & NIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$34.32

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Logo Nicolet Bankshares Inc.

NIC

Nicolet Bankshares Inc.

HOLD

Current Price

$162.61

Market Cap

3.2B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEAM
NIC
Founded
2017
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
3.2B
IPO Year
2019
2002

Fundamental Metrics

Financial Performance
Metric
BEAM
NIC
Price
$34.32
$162.61
Analyst Decision
Buy
Strong Buy
Analyst Count
12
3
Target Price
$50.75
$175.33
AVG Volume (30 Days)
2.1M
353.4K
Earning Date
05-06-2026
04-21-2026
Dividend Yield
N/A
1.00%
EPS Growth
82.31
21.49
EPS
N/A
0.81
Revenue
$24,000.00
N/A
Revenue This Year
N/A
$43.96
Revenue Next Year
$33.77
$26.91
P/E Ratio
N/A
$199.20
Revenue Growth
33.33
N/A
52 Week Low
$15.60
$114.12
52 Week High
$36.88
$163.11

Technical Indicators

Market Signals
Indicator
BEAM
NIC
Relative Strength Index (RSI) 59.75 71.36
Support Level $26.96 $141.32
Resistance Level $36.44 N/A
Average True Range (ATR) 2.18 4.77
MACD 0.34 2.09
Stochastic Oscillator 68.09 95.85

Price Performance

Historical Comparison
BEAM
NIC

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

About NIC Nicolet Bankshares Inc.

Nicolet Bankshares Inc is a United States-based bank holding company's principal business is banking, consisting of lending and deposit gathering, as well as ancillary banking-related products and services, to businesses and individuals of the communities it serves, and the operational support to deliver, fund and manage. It offers a variety of loans, deposits, and related services to business customers especially small and medium-sized businesses and professional concerns, business deposit products, cash management services, international banking services, business loans, lines of credit, commercial real estate financing, construction loans, agricultural real estate or production loans, and letters of credit, as well as retirement plan services.

Share on Social Networks: